309 related articles for article (PubMed ID: 17545540)
1. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
2. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
3. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
4. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).
Coral S; Sigalotti L; Gasparollo A; Cattarossi I; Visintin A; Cattelan A; Altomonte M; Maio M
J Immunother; 1999 Jan; 22(1):16-24. PubMed ID: 9924695
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M
Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
7. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
8. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
9. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
10. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
11. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
13. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
15. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
16. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
17. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
18. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
19. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
20. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.
Calabrò L; Fonsatti E; Altomonte M; Pezzani L; Colizzi F; Nanni P; Gattei V; Sigalotti L; Maio M
J Cell Physiol; 2005 Feb; 202(2):474-7. PubMed ID: 15389591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]